ES2537221B2 - PIRIDAZINO SALTS [2,3-a] PIRROLO [2,1-c] QUINOXALINIO FOR THE TREATMENT OF INFECTIONS BY LEISHMANIA AND DISEASES IN WHICH THE THYROSINE PHOSPHATE PROTEIN IS IMPLIED 1B - Google Patents

PIRIDAZINO SALTS [2,3-a] PIRROLO [2,1-c] QUINOXALINIO FOR THE TREATMENT OF INFECTIONS BY LEISHMANIA AND DISEASES IN WHICH THE THYROSINE PHOSPHATE PROTEIN IS IMPLIED 1B Download PDF

Info

Publication number
ES2537221B2
ES2537221B2 ES201331052A ES201331052A ES2537221B2 ES 2537221 B2 ES2537221 B2 ES 2537221B2 ES 201331052 A ES201331052 A ES 201331052A ES 201331052 A ES201331052 A ES 201331052A ES 2537221 B2 ES2537221 B2 ES 2537221B2
Authority
ES
Spain
Prior art keywords
leishmania
diseases
treatment
quinoxalinio
piridazino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES201331052A
Other languages
Spanish (es)
Other versions
ES2537221A1 (en
Inventor
Antonio JIMÉNEZ RUIZ
Kilian GUTIERREZ VIÑAS
David Moreno Mateos
Patricia SÁNCHEZ ALONSO
Ramón ALAJARÍN FERRÁNDEZ
Juan José Vaquero López
Julio ÁLVAREZ-BUILLA GÓMEZ
Mercedes GRIERA MERINO
María Luisa DÍEZ MARQUÉS
Diego RODRÍGUEZ PUYOL
Manuel RODRÍGUEZ PUYOL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad de Alcala de Henares UAH
Original Assignee
Universidad de Alcala de Henares UAH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad de Alcala de Henares UAH filed Critical Universidad de Alcala de Henares UAH
Priority to ES201331052A priority Critical patent/ES2537221B2/en
Priority to PCT/ES2014/070568 priority patent/WO2015004304A1/en
Publication of ES2537221A1 publication Critical patent/ES2537221A1/en
Application granted granted Critical
Publication of ES2537221B2 publication Critical patent/ES2537221B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

Esta invención está relacionada con nuevos compuestos de Fórmula I, con métodos para prepararlos, con el uso de los mismos como inhibidores del crecimiento del parásito Leishmania y/o como inhibidores de proteína tirosina fosfatasa 1B (PTP1B), con el uso de los intermedios que conducen a dichos compuestos para preparar un inhibidor del crecimiento del parásito de Leishmania y/o un inhibidor de PTP1B comprendido por dicha Fórmula, y con el uso de las composiciones farmacéuticas que contienen dichos compuestos para el tratamiento de enfermedades causadas por la infección por el parásito Leishmania y/o de las enfermedades en las que la PTP1B está implicada en la patogénesis.This invention is related to new compounds of Formula I, with methods for preparing them, with the use thereof as growth inhibitors of the Leishmania parasite and / or as protein tyrosine phosphatase 1B inhibitors (PTP1B), with the use of intermediates lead to said compounds to prepare a Leishmania parasite growth inhibitor and / or a PTP1B inhibitor comprised by said Formula, and with the use of pharmaceutical compositions containing said compounds for the treatment of diseases caused by parasite infection Leishmania and / or diseases in which PTP1B is involved in the pathogenesis.

Description

imagen1image 1

imagen2image2

imagen3image3

imagen4image4

imagen5image5

imagen6image6

imagen7image7

imagen8image8

imagen9image9

imagen10image10

imagen11image11

imagen12image12

imagen13image13

imagen14image14

imagen15image15

imagen16image16

imagen17image17

imagen18image18

imagen19image19

imagen20image20

imagen21image21

imagen22image22

imagen23image23

imagen24image24

imagen25image25

imagen26image26

imagen27image27

imagen28image28

imagen29image29

imagen30image30

imagen31image31

imagen32image32

imagen33image33

imagen34image34

imagen35image35

imagen36image36

imagen37image37

imagen38image38

imagen39image39

imagen40image40

imagen41image41

imagen42image42

imagen43image43

imagen44image44

imagen45image45

imagen46image46

imagen47image47

Claims (1)

imagen1image 1 imagen2image2 imagen3image3 imagen4image4 imagen5image5 imagen6image6 imagen7image7 imagen8image8 imagen9image9 imagen10image10 imagen11image11 imagen12image12 imagen13image13 imagen14image14
ES201331052A 2013-07-10 2013-07-10 PIRIDAZINO SALTS [2,3-a] PIRROLO [2,1-c] QUINOXALINIO FOR THE TREATMENT OF INFECTIONS BY LEISHMANIA AND DISEASES IN WHICH THE THYROSINE PHOSPHATE PROTEIN IS IMPLIED 1B Active ES2537221B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES201331052A ES2537221B2 (en) 2013-07-10 2013-07-10 PIRIDAZINO SALTS [2,3-a] PIRROLO [2,1-c] QUINOXALINIO FOR THE TREATMENT OF INFECTIONS BY LEISHMANIA AND DISEASES IN WHICH THE THYROSINE PHOSPHATE PROTEIN IS IMPLIED 1B
PCT/ES2014/070568 WO2015004304A1 (en) 2013-07-10 2014-07-10 Salts of pyridazino[2,3-a]pyrrolo[2,1-c]quinoxaline for the treatment of leishmania infections and diseases that involve the protein tyrosine phosphatase 1b

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201331052A ES2537221B2 (en) 2013-07-10 2013-07-10 PIRIDAZINO SALTS [2,3-a] PIRROLO [2,1-c] QUINOXALINIO FOR THE TREATMENT OF INFECTIONS BY LEISHMANIA AND DISEASES IN WHICH THE THYROSINE PHOSPHATE PROTEIN IS IMPLIED 1B

Publications (2)

Publication Number Publication Date
ES2537221A1 ES2537221A1 (en) 2015-06-03
ES2537221B2 true ES2537221B2 (en) 2015-10-09

Family

ID=52279384

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201331052A Active ES2537221B2 (en) 2013-07-10 2013-07-10 PIRIDAZINO SALTS [2,3-a] PIRROLO [2,1-c] QUINOXALINIO FOR THE TREATMENT OF INFECTIONS BY LEISHMANIA AND DISEASES IN WHICH THE THYROSINE PHOSPHATE PROTEIN IS IMPLIED 1B

Country Status (2)

Country Link
ES (1) ES2537221B2 (en)
WO (1) WO2015004304A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108409743B (en) * 2018-03-07 2021-05-04 兰州大学 Preparation method of alkyl nitrile substituted pyrrolo [1,2-a ] quinoxaline compound
WO2023057394A1 (en) 2021-10-04 2023-04-13 Forx Therapeutics Ag N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer

Also Published As

Publication number Publication date
ES2537221A1 (en) 2015-06-03
WO2015004304A1 (en) 2015-01-15

Similar Documents

Publication Publication Date Title
CO2020007218A2 (en) New benzylamino-substituted pyridopyrimidinones and derivatives as sos1 inhibitors
CL2018003681A1 (en) Boronic acid derivatives and therapeutic uses thereof
GT201600123A (en) SYK INHIBITORS
DOP2016000281A (en) IMIDAZO COMPOUNDS [4,5-C] QUINOLIN-2-ONA AND ITS USE TO TREAT CANCER
CR20150610A (en) PIRIMIDINE COMPOUNDS REPLACED AND DERIVATIVES TO COMBAT ANIMAL PESTS
CU20180152A7 (en) PYRIMIDIN-2-ILAMINO-1H-PYRAZOLES USEFUL AS LRRK2 INHIBITORS
NI201500120A (en) BIARIL COMPOUNDS - AMIDA AS KINASE INHIBITORS
PE20151501A1 (en) PRMT5 INHIBITORS AND THEIR USES
BR112016015838A8 (en) heterocyclic aromatic compounds, pharmaceutical composition comprising said compounds and combination product
CU20190101A7 (en) SUBSTITUTED DIAZABICYCLIC IMIDAZOPYRIMIDINES
CL2018001569A1 (en) Heteroaromatic compounds as btk inhibitors
UY33337A (en) SUBSTITUTED DERIVATIVES OF 1H-PIRAZOL [3,4-d] PYRIMIDINE AS INHIBITORS OF PHOSFOINOSITIDE 3-KINASES
DOP2014000036A (en) PIRIDAZINONE COMPOUNDS AND ITS USE AS DAAO INHIBITORS
AR102981A1 (en) INHIBITORS OF CELL NECROSIS AND METHODS OF PREPARATION OF THE SAME
AR113803A1 (en) PYRIMIDINE COMPOUND AS INHIBITOR OF JAK KINASES
CL2019002079A1 (en) Pim kinase inhibitor salts; useful in the treatment of cancer. (divisional request 201800611)
UY36875A (en) BROMODOMINIUM INHIBITING COMPOSITIONS FOR THE TREATMENT OF VARIOUS DISEASES
UY35455A (en) TRIPEPTIDIC INHIBITORS OF PROTEASA EPOXYCETONE
ES2543957T3 (en) New pharmaceutical composition for the treatment of fungal infections
CL2019002900A1 (en) Benzoazepine analogs as bruton tyrosine kinase inhibitors.
UY35344A (en) OESTRA-1,3,5 (10), 16-TETRAENE-3-CARBOXAMIDS
MX2020003495A (en) Boronic acid derivatives and synthesis thereof.
DOP2016000308A (en) COMPOUNDS OF 1, 3, 4-TIADIAZOL AND USE OF THE SAME FOR THE TREATMENT OF CANCER
CO2021007173A2 (en) Heteroaromatic compounds as vanin inhibitors
CO2021002225A2 (en) Heteroaromatic compounds as vanin inhibitors

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2537221

Country of ref document: ES

Kind code of ref document: B2

Effective date: 20151009